Revenue ₹3,901 Cr (+15.1% YoY)
0 met · 0 close · 3 missed across 3 tracked promises
View all executive profiles for Glenmark Pharmaceuticals LimitedGlenmark delivered a strong Q3 with consolidated revenue of ₹3,962 crore, up 15.1% YoY, driven by broad-based growth...
0% promises delivered
Based on 3 tracked promises across 3 quarters
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Quarterly Earnings Timeline
Financial verification status, call summary, sentiment, and management-delivery signals by quarter.
Q3 FY26
10 Feb 2026
Revenue ₹3,901 Cr (+15.1% YoY)
Glenmark delivered a strong Q3 with consolidated revenue of ₹3,962 crore, up 15.1% YoY, driven by broad-based growth across markets and currency tailwinds.
bullish
high
2 missed
Read full analysis →
Q2 FY26
30 Oct 2025
Revenue ₹6,047 Cr (+76% YoY)
Glenmark's Q2 FY26 consolidated revenue surged 76% YoY to ₹6,047 crore, driven by the ISB 2001 out-licensing deal which contributed ₹4,466 crore in North America.
bullish
high
1 missed
Read full analysis →
Q1 FY26
06 Aug 2025
Revenue ₹3,264 Cr (+0.6% YoY)
Glenmark's Q1 FY26 consolidated revenue was flat at ₹3,264 crore (+0.6% YoY), with India formulation growing 3.7% (secondary sales +15.1%) and North America up 8.9% Qo...
neutral
medium
Scorecard starts after historical backfill
Read full analysis →